do not combine dpp-4 inhibitors with glp-1 receptor agonists guideline The effect of DPP Role of Dipeptidyl Peptidase 4

Comparing them directly is like comparing a gentle breeze to a hurricane

Key drug-disease associations covered include: 1

This consensus-based guidance, which includes an outline of eight key nutritional priorities to support patients on GLP-1 medications, reflects the top interdisciplinary recommendations to help clinicians support patients receiving GLP-1 receptor agonists for obesity care with evidence-based nutritional and behavioral strategies

The greatest concern is that while in the short-term the program could provide health benefits to those who need help with weight management, in the long-term those same problems could return if there is a failure to extend the program past its current end date, Beene said

Diabetes 41 , 467473 (2023)

Other common side effects include: Dizziness and lightheadedness, particularly during the first few weeks Fatigue and low energy , often related to reduced caloric intake Headaches , which typically resolve within the first month Sulfur burps , a distinctive and common complaint Diarrhea , which usually resolves as the body adjusts Injection site reactions including redness and mild swelling Less common but important considerations Some patients experience hair loss on GLP-1 medications